Quality of life of patients with pulmonary arterial hypertension: a meta-analysis
- PMID: 34355370
- DOI: 10.26355/eurrev_202108_26455
Quality of life of patients with pulmonary arterial hypertension: a meta-analysis
Abstract
Objective: Pulmonary arterial hypertension (PAH) is a rare condition, with an incidence of 15-50 cases per million annually. Available studies demonstrate that despite the longer survival of PAH patients, their quality of life (QoL) deteriorates as the condition progresses. Consequently, the goals of PAH therapy have expanded from increasing survival to improving health-related quality of life. The objective of this systematic review and meta-analysis was to summarize the available evidence about the level of QoL in patients with PAH.
Materials and methods: A systematic search was performed using the Cochrane guidelines for conducting meta-analysis following the PRISMA statement. The meta-analysis includes findings from 11 studies evaluating the QoL of PAH patients at baseline and at follow-up (12 weeks) using the Short Form (36) Health Survey (SF-36), the Minnesota Living with Heart Failure Questionnaire (MLHFQ) and the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).
Results: The mean physical component score (SF-36) for the group was 37.2 points (95% CI: 33.24-41.16) and the heterogeneity coefficient was I²=97.71% (p < 0.001). The mean mental component score (SF-36) was 46.38 (95% CI: 44.21-48.56) and the heterogeneity coefficient was I²=87.92% (p < 0.001). The result indicates improved QoL 12 weeks after the intervention, though three papers did not fully confirm this. The greatest improvement in QoL was found in patients treated with bosentan and iloprost and the smallest improvement in QoL was found in patients treated with epoprostenol sodium. The heterogeneity coefficient was I²=91.36%, p < 0.001 for CAMPHOR and I²=97.65%, p < 0.001 for MLHFQ.
Conclusions: PAH patients tend to have a poor QoL, mainly in the physical functioning domain, less so in the psychological functioning domain. QoL may be improved by therapeutic interventions, mainly pharmaceutical ones. Patients with PAH also tend to suffer from depression, anxiety, stress, or sleep disorders. All these factors are significantly correlated with poorer QoL.
Similar articles
-
Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.Am J Cardiovasc Drugs. 2021 Mar;21(2):181-191. doi: 10.1007/s40256-020-00426-w. Am J Cardiovasc Drugs. 2021. PMID: 32918210
-
Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.Respir Care. 2017 Apr;62(4):489-496. doi: 10.4187/respcare.05280. Epub 2017 Jan 24. Respir Care. 2017. PMID: 28119496 Clinical Trial.
-
Role of iloprost and bosentan in pulmonary arterial hypertension.Niger J Med. 2008 Jan-Mar;17(1):13-9. doi: 10.4314/njm.v17i1.37347. Niger J Med. 2008. PMID: 18390125 Review.
-
Bosentan therapy in patients with pulmonary arterial hypertension: the relationship between improvements in 6 minute walk distance and quality of life.Respirology. 2008 Sep;13(5):674-82. doi: 10.1111/j.1440-1843.2008.01326.x. Respirology. 2008. PMID: 18713089
-
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy.Chest. 2005 Aug;128(2):709-13. doi: 10.1378/chest.128.2.709. Chest. 2005. PMID: 16100158 Clinical Trial.
Cited by
-
Pulmonary hypertension.Nat Rev Dis Primers. 2024 Jan 4;10(1):1. doi: 10.1038/s41572-023-00486-7. Nat Rev Dis Primers. 2024. PMID: 38177157 Review.
-
The PAH patient's perspective.Int J Cardiol Congenit Heart Dis. 2025 May 26;21:100596. doi: 10.1016/j.ijcchd.2025.100596. eCollection 2025 Sep. Int J Cardiol Congenit Heart Dis. 2025. PMID: 40546754 Free PMC article. Review.
-
Metabolic Alterations Associated With Right Ventricular Dysfunction in Pulmonary Arterial Hypertension: The Modulatory Effects and Improvement Mechanisms of Exercise.Rev Cardiovasc Med. 2025 Jul 30;26(7):37460. doi: 10.31083/RCM37460. eCollection 2025 Jul. Rev Cardiovasc Med. 2025. PMID: 40776975 Free PMC article. Review.
-
Patient Satisfaction with a Dedicated Infusion Pump for Subcutaneous Treprostinil to Treat Pulmonary Arterial Hypertension.J Pers Med. 2023 Feb 26;13(3):423. doi: 10.3390/jpm13030423. J Pers Med. 2023. PMID: 36983605 Free PMC article.
-
Long-term outcomes in health-related quality of life influence chronic disease management in patients with pulmonary hypertension.Front Cardiovasc Med. 2022 Nov 10;9:1008253. doi: 10.3389/fcvm.2022.1008253. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 36440006 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical